Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I been hearing 'bout Grapefruits ;)
..public voice of the shorts..
..hedge raid across the board.. few got away.. IMO the game got stopped
..take the $$ and run.. ;)
I remember the 2014 Marijuana Bull run, Man.. that was crazy and we are way closer to the legalization of marijuana now more than ever..
So I'm buying MJ's here and there SNDL was said to have problems in over-production w/out places to sell it in the past.. then they mentioned going retail .. these sound like good problems to have while getting connected with other companies in the same space.. just my opinion..
The republicans want to push back on legalization so I guess the Dem's have a 2 year window to push it through.. I'm guessing they'll go for it sooner than later.. that's why I'm here.
"but diluting shareholder value" IMO it can go either way.. it takes money to make money and these moves could possibly position us in good way.. but like you said timing.. I just bought a small amount that I'm not really concerned about.. active traders will see it differently.. :)
$SNDL (copy) I emailed SNDL Corporate. From ya-h00:
I got a response. And this is what I received below.?? I figured I would share.?
Hi Kenny,
Thanks for your email. As publicly disclosed, we continue to review strategic alternatives to enhance shareholder value. Sundial has not currently identified the need to access the shelf offering, however it is available as a source of capital over the next 3 years should accretive opportunities arise. We currently have a significant cash reserve on hand to provide operational stability and flexibility along with the ability to review and execute strategic investments as the Company continues on the path to sustainable profitability. Sundial intends to use the proceeds, if any, from this offering for the financing of possible acquisitions of, or investments in, equipment, facilities, assets, equity or debt of other businesses, products or technologies and for working capital and general corporate purposes. We have no announcement of any specific use of any potential net proceeds at this time. We are working hard with complete focus on providing long-term shareholder value.
Thanks again for your email.
Sophie
-----Original Message-----
From: Kenny “Kkkaufman7
Sent: February 18, 2021 3:51 PM
To: Sophie Pilon
Subject: Please reverse the shelf
$SNDL From ya-h00: I emailed SNDL Corporate.
I got a response. And this is what I received below.?? I figured I would share.?
Hi Kenny,
Thanks for your email. As publicly disclosed, we continue to review strategic alternatives to enhance shareholder value. Sundial has not currently identified the need to access the shelf offering, however it is available as a source of capital over the next 3 years should accretive opportunities arise. We currently have a significant cash reserve on hand to provide operational stability and flexibility along with the ability to review and execute strategic investments as the Company continues on the path to sustainable profitability. Sundial intends to use the proceeds, if any, from this offering for the financing of possible acquisitions of, or investments in, equipment, facilities, assets, equity or debt of other businesses, products or technologies and for working capital and general corporate purposes. We have no announcement of any specific use of any potential net proceeds at this time. We are working hard with complete focus on providing long-term shareholder value.
Thanks again for your email.
Sophie
-----Original Message-----
From: Kenny “Kkkaufman7
Sent: February 18, 2021 3:51 PM
To: Sophie Pilon
Subject: Please reverse the shelf
~ Marijuana legalization ~ ..I wonder did the powers that be set Carlos and Co. up in another shop.. will Merida step in.. Will GL Brands become Merida Capital Partners central.. The core of the Octopus enterprise.. ?
~ Marijuana legalization ~
$SNDL Sundial Growers Inc. has 52 institutional owners and shareholders that have filed 13D/G or 13F forms with the SEC These institutions hold a total of 22,682,873 shares. Largest shareholders include Susquehanna International Group, Llp, Millennium https://fintel.io/so/us/sndl
$SNDL Sundial Growers Inc. has 52 institutional owners and shareholders that have filed 13D/G or 13F forms with the SEC These institutions hold a total of 22,682,873 shares. Largest shareholders include Susquehanna International Group, Llp, Millennium
https://fintel.io/so/us/sndl
APYP to hold Annual Shareholder Meeting instead of Zoom Call. https://www.otcmarkets.com/stock/APYP/news/APYP-Update?id=290348
.03 Thursday
thanks x's 2
How much does anyone predict as a buy-out ? Thanks
..will there be sell on the 18th talk or will people grow a set ?
oh sorry.. didn't realize the heading was cut out.. DD by teaser on ya-h00 10 reply thread..
$RLFTF (related) From brpa umbrella 3 days ago:
January 2021 Archives of Pathology and Laboratory Medicine.
Patients who die of Covid not only have Diffuse Alveolar Damage but also bronchopneumonia, aspiration pneumonia and fibrin thromoemboli is small lung vessels.
Only Aviptadil, with its multimodal therapeutic actions, helps mitigate all four of these pathologic conditions. Archives of Pathology and Laboratory Medicine Volume 145; pages 11 through 21; January 2021 issue.
https://allen.silverchair-cdn.com/allen/content_public/journal/aplm/pap/10.5858_arpa.2020-0786-sa/2/10.5858_arpa.2020-0786-sa.pdf?Expires=1616513950&Signature=J~8JDKMinmuztSRGUg0HIa5r7s-gwvt1uHiQnV4hM5EpC1YdOrLHyao7Lrnu5I1ZbYi3je0A5qUsdaiuSS6JZyWFNbDCoW1AWAQFYOBxHL4n0S3PGpfL8ZT2WoTyh-EM1T5zTUK5DBtLMbHdAVwqTbVJ35vW06yee9DFjApRBHCD-W7El62-92vq0~my9gcS08Uw6EMNmDFYMYO8dgYQd3QnBNkuOyKT6RdRz9QTtuAZnJYkm9sP3S-2UdVhfORM9Yn2lptHxLHyItGYNYNfARSnYvelcuSwp8aGBT~atWzC65ta0YYwGsIWlGfofdFgmDUSu4RzlM77uRvjhIWDig__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA
$RLFTF Branden DD (opinion) post -Ya-h00 - Many people don’t realize how many high flow nasal cannula covid patients there are in hospitals. This isn’t just a tiny, insignificant subgroup of hospitalized covid patient.
There are literally designated floors in hospitals across the country made up entirely of noninvasive ventilated covid patients.
Multiple floors even within the same hospital. Many hospitals require these patients to only go to the intensive care unit but some allow for them to go to what’s called intermediate care units.
These high flow nasal cannula (hfnc) patients sit here often for weeks or even longer with the hope that respiratory failure will improve so we can titrate that fi02(oxygen concentration) down accordingly to a nasal cannula and then to room air allowing for discharge home.
(Sometimes home on 2 ltr nasal cannula). Some patients do well and you’re able to titrate down, however a ton of hfnc patients don’t do well once their admitted.
Their disease process worsens and you have to titrate fiO2 up on the hfnc. Sometimes they decompensate to the point where they need to be mechanically ventilated.
But Imagine if we give zyesami to all of these patients the minute they require high volumes of oxygen such as a hfnc.
You come into the emergency room, you’re diagnosed with covid pneumonia requiring hfnc at 70% fiO2, we’re going to immediately start a zyesami infusion and send you up to an intercare or icu bed.
11 days isn’t insignificant, 11 days is HUGE.
Something biologically is happening to decrease that hospital time and I guarantee you if their hospital stay is shortened that significantly, then respiratory failure will be resolving more frequently.
I want to know how many zyesami hfnc patients DONT have to get intubated because they got our drug.
Excited stuff on the horizon guys. EUA within our future.
NeuroRx CEO says Zyesami trial shows promising results for critically ill COVID-19 patients
link
Fire doused at FuellCell Energy in Torrington
BY BRIGITTE RUTHMAN REPUBLICAN-AMERICANFebruary 15, 2021
https://www.rep-am.com/local/localnews/2021/02/15/fire-doused-at-fuellcell-energy-in-torrington/
...Imagine proof readers do well in the stock market.. :)
Thank you :)
..someone asked about the word partner ..in the fill/finish.. more info please.. ? they're just part of the process in IV use.. ? Thanks
$RLFTF DD by Sparks (copy) : Sharing a summary of the interview with Dr. Javitt I put together for myself because of the confusion this week with PRs etc. Dr. Javitt appeared to be confident and very encouraging.
Regarding primary endpoint: The primary endpoint is recovery from respiratory failure - meaning patients get better and go home - it is NOT mortality. This was discussed with the FDA early on in the study, along with a timeline of 60 days based on what they saw with Dr. Youssef's open label study at Houston Methodist last fall. The 28 day timeline was included originally because that has been the historical standard since the 90's for ARDS studies but it isn't really relevant anymore. The FDA told them that ultimately they care about how patients feel, function and survive.
Regarding the timeline: the last patient was enrolled on Dec 24 and Day 60 for that patient will be February 20th. At Houston Methodist, they achieved statistical significance and a larger difference between days 28 and 60.
Regarding the release of topline data to the public: they are tracking and cleaning it in real-time and not waiting for the last patient but it can still take a week or two after the last patient is finished to look at the entire dataset and clean up discrepancies etc.
Regarding the EUA: they don't have to submit a new application and they are building off of the previous application from last fall by adding important new data from this study. The FDA told them they wanted randomized control data to make a decision about the EUA and so they are providing that now. The drug did not have a meaningful safety database previously either until now, and so they can now say with confidence that it is safe.
Regarding additional information: For additional supportive information they are having radiologists review x-rays in a blinded manner to see if they are consistent with the open label results.
Regarding the PRs: They released the PR this week because it is material information that investors should be aware of and it is significant because there is a precedent with Remdesivir as it was approved for EUA based on a statistically significant reduction in hospital days and Zyesami shows this as well in a more significant way.
Regarding the significance of secondary endpoints like reduced hospital days, reduced ICU days and improved NIAID scores : They are showing statistical significance across the board. There are obviously the financial and logistical benefits to having people go home earlier, but more importantly for the study it shows that something biological happened to get them better and home sooner. they now need to look at the data further to calculate the time to resolution for respiratory failure.
Regarding manufacturing: they have teamed with Nephron Pharma for the inhaled sterile products and are feeling good about that, they have built a supply chain and can supply as much raw material (aviptadil is the raw material) as needed in North America and Israel now and within a few months will have enough for the rest of the world.
Regarding marketing: Robert Besthof is handling building up a commercially capable company. Some large partnerships will be announced in the near future regarding this. He did say that Cardinal Health is the logistics partner that can get the drug anywhere overnight.
He isn't too worried about marketing - if the FDA grants the EUA people will know about it and Drs will want it - the drug speaks for itself. Regardless they have a team, a plan in place and some partnerships they will be announcing.
He talked about a bunch of other stuff like requirements for NDA (new drug approval) versus EUA, the inhaled trial they have started with UC Irvine and will announce additional study sites in the next few weeks, how Zyesami is included in the I-SPY trial supported by Barda that will compare multiple promising new drugs against each other (this will be the inhaled version), they are actively looking into chronic covid longhaulers and how this can help with acute lung injury. He said that even if covid disappears in a year ARDS continues to be a problem and the previous studies for this didn't advance mainly due to no commercial supply or long term formulation available. He said that Zyesami should work with the new variants because of what it targets as opposed to vaccines that target a specific protein. They are working on standing up a research program in the next couple of months to measure this.
A great call and put my mind at ease - I hope this helps you if you don't have time to watch the video.
Does this count people who are on Vent/ECMO who later pass after the "plug is pulled" ? and will the 60 day reveal better survival w/VIP ?
RE: They have never reported, so far as I know, significant mortality improvement at 28 days.
..holding up.. new base looking good for further upside IMO ..'n it's still undiscovered..
$RLFTF (related) Dr Yo asked all the good questions and Dr J. gave a lot of new insight..
$RLFTF in 20 min. youtube ZYESAMI (Aviptadil, RLF-100) COVID-19 Phase 2/3 Trial Results: Decreased Length Of Hospitalization?
translated: ?We are facing a third wave of infections in Europe (not just in the EU).... we need to protect our hospitals----and that's certainly not just possible with vaccines (where we now know that a mutation has problems... mutations will follow...!) ?
? In this complex context we know-- our Medi has a lot of effect --- never ?
? forget?
Dr J's your man..
..some are saying they want to buy us out and tried to kick our value down.. that's hmmmmm
$APYP The next Zoom meeting is for February 18, 2021, at 4:30 PM EST (the USA and Canada)
APYP ZOOM CALL UPDATE
Boca Raton, FL (OTC APYP) January 20, 2021- The management of AppYea Inc. send a sincere thank you to the 422 participants that registered for the initial Zoom Call. The initial part of the presentation lasted about 20 minutes. I received messages people were still on Zoom or even trying to log in, so I logged back into the Zoom call 5 minutes later and handled an impromptu Q&A session that lasted about an hour. I want to thank the 199 participants that were involved in the Q&A session. If you missed any portion of the Zoom meeting, both recordings are now available on www.appyea.com under the news section. "I was expecting about 40 people and was overwhelmed with the mass volume of people and the initial technical issues getting people into the meeting. If any shareholder has questions, please email me directly at tviolette310@gmail.com. I am using this email until we can completely update the website and activate the email service properly. Thank you for your support and being patient while we are trying to grow the Company."
The next Zoom meeting is for February 18, 2021, at 4:30 PM EST (the USA and Canada)
Join Zoom Meeting
https://us02web.zoom.us/j/83957414151?pwd=aDhlQmNlc1l1L3BYdjdtYTlieVErZz09
Meeting ID: 839 5741 4151
Passcode: APYP
$APYP The next Zoom meeting is for February 18, 2021, at 4:30 PM EST (the USA and Canada)
APYP ZOOM CALL UPDATE
Boca Raton, FL (OTC APYP) January 20, 2021- The management of AppYea Inc. send a sincere thank you to the 422 participants that registered for the initial Zoom Call. The initial part of the presentation lasted about 20 minutes. I received messages people were still on Zoom or even trying to log in, so I logged back into the Zoom call 5 minutes later and handled an impromptu Q&A session that lasted about an hour. I want to thank the 199 participants that were involved in the Q&A session. If you missed any portion of the Zoom meeting, both recordings are now available on www.appyea.com under the news section. "I was expecting about 40 people and was overwhelmed with the mass volume of people and the initial technical issues getting people into the meeting. If any shareholder has questions, please email me directly at tviolette310@gmail.com. I am using this email until we can completely update the website and activate the email service properly. Thank you for your support and being patient while we are trying to grow the Company."
The next Zoom meeting is for February 18, 2021, at 4:30 PM EST (the USA and Canada)
Join Zoom Meeting
https://us02web.zoom.us/j/83957414151?pwd=aDhlQmNlc1l1L3BYdjdtYTlieVErZz09
Meeting ID: 839 5741 4151
Passcode: APYP
This is a clip from a PR from another MJ/CBD company..
There is a sense of relief that 2020 is now behind us. Over the course of the past year, the impact of COVID-19 has been felt around the globe and will undoubtedly continue to impact countless lives and entire economies for years to come. While many difficulties remain before us all, a guarded optimism is growing daily.
The challenges that directly impacted our venture were principally logistical and operational in nature and affected most of the sector equally.
Given the Israeli governments increasingly pragmatic outlook regarding cannabis we remain extremely optimistic regarding our ability to achieve our strategic goals for the new year.
-------
..with the cuts in pay and BK protection moves I have no problem seeing the results of a beat down on the company.. I have a feeling they're scrappy and still in the fight.. but it may be good for others to hear they're gonna go the distance. ..maybe Merida should consider a release.. unless they're buying up their own shares on the low.. who the ..k knows..
...the brass plumbing holds up way longer than the plastic !!!
;)
$APYP ..this chickens 'bout to hatch..
$RLFTF (related) Dr. Yo, M.D., M.P.H. @YoDoctorYo The legend Dr. Javitt from @NeuroRxPharma is joining me to discuss trial data #Aviptadil #RLFTF $RLFTF
on Thursday February 11 at 9am EST